| Literature DB >> 27366646 |
Yuejun Tian1, Yuwen Gong1, Yangyang Pang1, Zhiping Wang1, Mei Hong1,2.
Abstract
Background. Epidemiological studies have reported various results relating preoperative hydronephrosis to upper tract urothelial carcinoma (UTUC). However, the clinical significance and prognostic value of preoperative hydronephrosis in UTUC remains controversial. The aim of this study was to provide a comprehensive meta-analysis of the extent of the possible association between preoperative hydronephrosis and the risk of UTUC. Methods. We searched PubMed, ISI Web of Knowledge, and Embase to identify eligible studies written in English. Summary odds ratios (ORs) or hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using fixed-effects or random-effects models. Results. Nineteen relevant studies, which had a total of 5,782 UTUC patients enrolled, were selected for statistical analysis. The clinicopathological and prognostic relevance of preoperative hydronephrosis was evaluated in the UTUC patients. The results showed that all tumor stages, lymph node status and tumor location, as well as the risk of cancer-specific survival (CSS), overall survival (OS), recurrence-free survival (RFS) and metastasis-free survival (MFS) were significantly different between UTUC patients with elevated preoperative hydronephrosis and those with low preoperative hydronephrosis. High preoperative hydronephrosis indicated a poor prognosis. Additionally, significant correlations between preoperative hydronephrosis and tumor grade (high grade vs. low grade) were observed in UTUC patients; however, no significant difference was observed for tumor grading (G1 vs. G2 + G3 and G1 + G2 vs. G3). In contrast, no such correlations were evident for recurrence status or gender in UTUC patients. Conclusions. The results of this meta-analysis suggest that preoperative hydronephrosis is associated with increased risk and poor survival in UTUC patients. The presence of preoperative hydronephrosis plays an important role in the carcinogenesis and prognosis of UTUC.Entities:
Keywords: Clinicopathological; Meta-analysis; Preoperative hydronephrosis; Prognosis; Upper tract urothelial carcinoma
Year: 2016 PMID: 27366646 PMCID: PMC4924132 DOI: 10.7717/peerj.2144
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Flow chart showing the study selection process.
Summary of the characteristics of enrolled studies.
| Study | Country | Patients | Study period | Age (range), yr | Gender (m/f) | Cut off (Present/High grade) | FU (range), mon | NOS score |
|---|---|---|---|---|---|---|---|---|
| Cho˙2007 | Korea | 104 | 1986–2004 | Md = 65(25–91) | 66/38 | Grade 0/1/2 vs. 3/4 on CT, EU, US | Md = 44(6–214) | 7 |
| Chapman˙2009 | USA | 308 | 1996–2006 | Mn = 66.4(29.7–90.4) | 236/72 | Absence vs. presence on CT, US, MRI, IVU | NA | 8 |
| Ng˙2011 | USA | 106 | 1993–2005 | Md = 69(36–90) | 67/39 | Absence vs. presence on CT | Md = 47(1–164) | 8 |
| Messer˙2013 | USA | 408 | 1997–2008 | Md = 69.1(IQR, 15.5) | 254/154 | Mild/moderate vs. severe on CT, MRI, IVP, US | NA | 7 |
| Bozzini˙2013 | France | 401 | 1995–2010 | Md = 69.0(IQR, 60.0-76.0) | 249/152 | Absence vs. presence on CT, MRI, IVU | Md = 26(IQR, 9.0–49.0) | 8 |
| Zhang˙2013 | China | 217 | 2000–2010 | Md = 69(62–81) | 130/87 | Absence vs. presence on CT, MRI, IVP, US | Md = 52 | 8 |
| Hwang˙2013 | Korea | 114 | 2004–2010 | Md = 71(41–84) | 88/26 | None/mild vs. moderate/severe on CT, EU, US | Md = 26.5 (23.5–31) | 8 |
| Luo˙2013 | Taiwan | 162 | 2005–2010 | Mn = 67.97 | 81/81 | Grade 0/1/2 vs. 3/4 on urology radiologists | Md = 36.87 | 8 |
| Sakano˙2013 | Japan | 536 | 1995–2009 | Md = 71(32–93) | 370/166 | Absence vs. presence | Md = 40.9(3–200) | 7 |
| Chen˙2013 | China | 729 | 2002–2010 | Mn = 66.5(20–94) | 318/411 | Absence vs. presence on CT, MRI, IVU | NA | 7 |
| Zou˙2014 | China | 122 | 1999–2013 | Md = 64(35–80) | 87/35 | Absence vs. presence | Md = 53(3–159) | 8 |
| Colin˙2014 | France | 151 | 1995–2010 | Md = 72.5 (IQR, 63.4–78.1) | 98/53 | Absence vs. presence | Md = 18.5(IQR, 9.5–37.9) | 6 |
| Fradet ˙2014 | Canada | 743 | 1990–2010 | Mn = 69.7 | 438/304 | Absence vs. presence | Md = 24.8(IQR, 7.69–56.76) | 6 |
| Chung˙2014 | USA | 141 | 1998–2013 | Md = 70(35–92) | 91/50 | None/mild vs. moderate/severe on CT, IVP, US | Md = 34(1–149) | 8 |
| Yeh˙2015 | Taiwan | 472 | 1991–2013 | Md = 67(24–95) | 204/268 | Absence vs. presence on CT | Md = 33(1–233) | 7 |
| Zhang˙2015 | China | 520 | 2000–2010 | NA | 229/291 | Absence vs. presence on CT, MRI | Md = 54(12–151) | 8 |
| Liang˙2016 | China | 172 | 2001–2014 | Md = 70(IQR, 63–77) | 105/67 | None/mild vs. severe on CT, MRI, US | Md = 44(IQR, 24–62) | 7 |
| Xing˙2016 | China | 192 | 2000–2013 | NA | 114/78 | Absence vs. presence on CT, US | Md = 65(3–144) | 8 |
| Zhang˙2016 | China | 184 | 2006–2008 | Md = 70(61–75) | 84/100 | Absence vs. presence on CT, MRI, US | Md = 78(34–92) | 8 |
Notes.
computed tomography
excretory urography
follow-up
interquartile range
intravenous pyelogram
intravenous urograms
median
mean
magnetic resonance imaging
not available
ultrasound
month
year
HR values of the CSS, OS, RFS and MFS of the UTUC.
| Outcome | Studies ( | Patients | HR | 95% CI | Model | Heterogeneity | |
|---|---|---|---|---|---|---|---|
| I2, | |||||||
| CSS | 12 | 3,063 | 1.69 | 1.23–2.33 | 0.001 | Random | 70%, 0.001 |
| OS | 6 | 1,873 | 1.62 | 1.35–1.94 | 0.000 | Fixed | 17%, 0.30 |
| RFS | 7 | 695 | 1.95 | 1.26–3.04 | 0.003 | Random | 54%, 0.04 |
| MFS | 4 | 820 | 1.55 | 1.04–2.33 | 0.03 | Fixed | 27%, 0.25 |
Notes.
confidence interval
cancer-specific survival
fixed, inverse variance model
hazard ratio
I-squared
metastasis-free survival
overall survival
random, I–V heterogeneity model
recurrence-free survival
Figure 2(A) The hazard ratio (HR) of preoperative hydronephrosis associated with CSS in UTUC patients; (B) The hazard ratio (HR) of preoperative hydronephrosis associated with OS in UTUC patients.
OR values for the UTUC subgroups according to clinical characteristics.
| Outcome of interest | Studies | Patients | OR | 95% CI | Model | Heterogeneity | |
|---|---|---|---|---|---|---|---|
| I2, | |||||||
| Ta/1 vs. T2-4 | 9 | 2,462 | 3.12 | 1.85–5.27 | 0.000 | Random | 86%, 0.000 |
| High grade vs. Low grade | 3 | 799 | 1.66 | 1.20–2.29 | 0.002 | Fixed | 32%, 0.23 |
| G3 vs. G1 + G2 | 2 | 921 | 1.42 | 0.75–2.69 | 0.28 | Random | 76%, 0.04 |
| G2 + G3 vs. G1 | 2 | 921 | 0.94 | 0.49–1.79 | 0.85 | Fixed | 0%, 0.42 |
| Lymph node metastasis vs. No lymph node metastasis | 6 | 1,834 | 1.60 | 1.13–2.26 | 0.009 | Fixed | 0%, 0.55 |
| Renal pelvis vs. Ureter | 10 | 2,858 | 4.28 | 2.91–6.30 | 0.000 | Random | 78%, 0.000 |
| Recurrence vs. No recurrence | 2 | 737 | 1.28 | 0.92–1.77 | 0.14 | Fixed | 0%, 0.68 |
| Gender (Male vs. Female) | 7 | 2,556 | 1.01 | 0.86–1.19 | 0.90 | Fixed | 6%, 0.38 |
Notes.
confidence interval
fixed, inverse variance model
I-squared
odds ratio
random, I–V heterogeneity model
Figure 3Funnel plots were used to evaluate publication bias on CSS.
Begg’s test and Egger’s test were not significant indicating that no significant bias was observed on CSS (A and B).